Results 231 to 240 of about 60,957 (246)
NFκB/IL-6/JAK2/STAT axis in myelofibrosis is a key vulnerability that is targetable and relevant to JAK2 inhibitor treatment resistance. [PDF]
Blood Cancer JBian H +8 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
JAK2-mediated Intracellular Signaling
Current Molecular Medicine, 2021Janus kinase-2 (JAK2) is a non-receptor tyrosine kinase that serves key roles as the intracellular signaling effector of the cytokine receptor, such as mediating effects of leptin, erythropoietin, interferon, and growth hormone. A lot of molecular underlying mechanisms of JAK2 participation are known, however, additional signaling mechanisms of its ...
Mentor Sopjani +4 more
openaire +2 more sources
JAK2, the JAK2 V617F mutant and cytokine receptors
Pathologie Biologie, 2007Recently, a unique recurrent somatic mutation was identified as a major molecular event in polycythemia vera, essential thrombocythemia and idiopathic myelofibrosis. Expression of this mutant in cytokine-dependent hematopoietic cell lines induces autonomous growth. This effect is enhanced by overexpression of cytokine receptors, and can be inhibited by
J, Staerk +7 more
openaire +2 more sources
2021
Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell (HSC) disorders with overproduction of mature myeloid blood cells, including essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF). In 2005, several groups identified a single gain-of-function point mutation JAK2V617F in the majority of MPN patients.
openaire +2 more sources
Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell (HSC) disorders with overproduction of mature myeloid blood cells, including essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF). In 2005, several groups identified a single gain-of-function point mutation JAK2V617F in the majority of MPN patients.
openaire +2 more sources
Medicina Clínica, 2016
Resumen La inhibicion farmacologica de la actividad cinasa de las proteinas JAK permite interferir la senalizacion de las citocinas inmunomoduladoras y bloquear la activacion constitutiva de la via JAK-STAT que caracteriza a ciertas neoplasias, en particular a las mieloproliferativas cronicas.
Juan Carlos Hernández Boluda +2 more
openaire +1 more source
Resumen La inhibicion farmacologica de la actividad cinasa de las proteinas JAK permite interferir la senalizacion de las citocinas inmunomoduladoras y bloquear la activacion constitutiva de la via JAK-STAT que caracteriza a ciertas neoplasias, en particular a las mieloproliferativas cronicas.
Juan Carlos Hernández Boluda +2 more
openaire +1 more source
2010
The objective of the study, carried out between June 2009 and September 2010, is to determine the frequency of the JAK2 mutations in patients suffering from myeloproliferative neoplasms and investigate the possible correlations with the patient s clinical and laboratory findings.
openaire +1 more source
The objective of the study, carried out between June 2009 and September 2010, is to determine the frequency of the JAK2 mutations in patients suffering from myeloproliferative neoplasms and investigate the possible correlations with the patient s clinical and laboratory findings.
openaire +1 more source
Blood, 2013
Abstract Approximately 50% of myeloproliferative neoplasms (MPNs) harbor the JAK2 V617F mutation while approximately 50% of B-cell acute lymphoblastic leukemias (B-ALLs) with CRLF2 rearrangements harbor JAK2 exon 16 mutations that primarily involve R683.
Nadja Kopp +7 more
openaire +1 more source
Abstract Approximately 50% of myeloproliferative neoplasms (MPNs) harbor the JAK2 V617F mutation while approximately 50% of B-cell acute lymphoblastic leukemias (B-ALLs) with CRLF2 rearrangements harbor JAK2 exon 16 mutations that primarily involve R683.
Nadja Kopp +7 more
openaire +1 more source
A novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitination
Cellular Signalling, 2011AG490 is a tyrosine kinase inhibitor with activity against Jak2 and apoptotic activity in specific leukemias. Due to its weak kinase inhibitory activity and poor pharmacology, we conducted a cell-based screen for derivatives with improved Jak2 inhibition and activity in animals.
Vaibhav, Kapuria +8 more
openaire +2 more sources
2021
V617F mutation jak2 gene is an important diagnostic criterion for the diagnosis of chronic myeloproliferative disorders. The method of detection using RT-PCR and direct sequencing was propoused.
openaire +1 more source
V617F mutation jak2 gene is an important diagnostic criterion for the diagnosis of chronic myeloproliferative disorders. The method of detection using RT-PCR and direct sequencing was propoused.
openaire +1 more source